Activated c3 antibody

Catalog No. ABIN2192027

Product Details

Target: Activated c3

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Application: Immunoassay (IA), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Sterility: 0.2 μm filtered

Clone: BH6

Application Details

Application Notes: For immunohistology, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50.

Restrictions: For Research Use only

Handling

Buffer: PBS, containing 0.02 % sodium azide and 0.1 % bovine serum albumin.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for one year.

Expiry Date: 12 months

References

Lappegård, Fung, Bergseth, Riesenfeld, Lambris, Videm, Mollnes: "Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation." in: The Annals of thoracic surgery, Vol. 77, Issue 3, pp. 932-41, (2004) (PubMed).

Garred, Mollnes, Lea, Fischer: "Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c." in: Scandinavian journal of immunology, Vol. 27, Issue 3, pp. 319-27, (1988) (PubMed).

Garred, Mollnes, Lea: "Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3." in: Scandinavian journal of immunology, Vol. 27, Issue 3, pp. 329-35, (1988) (PubMed).

Target Details

Target: Activated c3

Background: The monoclonal antibody bH6 recognizes a neo-epitope expressed on the cleavage fragments of C3b, iC3b, and C3c. The complement system is an important factor in innate immunity. The third complement component, C3, is central to the classical, alternative and lectin pathways of complement activation. Activation products of the complement cascade contain neo-epitopes that are not present in the individual native components. Monoclonal antibodies detecting neo-epitopes have been used for direct quantification of activation at different steps in the complement cascade. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. C3 is the most abundant protein of the complement system with serum protein levels of about 1.3 mg/mL. An inherited deficiency of C3 predisposes the person to frequent assaults of bacterial infections. In ulcerative colitis, and idiopathic chronic inflammatory bowel disease, the deposition of C3 in the diseased mucosa has been reported. Proteolysis by certain enzymes results in the cleavage of C3 into C3a and C3b. C3b becomes attached to immune complexes and is further cleaved into iC3b, C3c, C3dg and C3f. The monoclonal antibody bH6 is specific for a C3 neo-epitope expressed on the cleavage fragments of C3b, iC3b, and C3c, but not C3dg and C3f.